Our data suggest that this degradation is mediated by the proteasome pathway, and in future work, it would be interesting to explore whether reduction of RILPL1 levels in WCLs is a useful biomarker for monitoring lysosomal dysfunction that is of relevance to PD. This evidence concerns the gene RILPL1 and Parkinson disease.